```html

Glanzmann Thrombasthenia – A Complete Patient Guide

Overview

Glanzmann thrombasthenia (GT) is a rare, inherited bleeding disorder caused by a defect in the platelet glycoprotein IIb/IIIa (integrin αIIbβ3) receptor. This receptor is essential for platelets to bind fibrinogen and form a stable clot. When it is absent or dysfunctional, patients experience abnormal bleeding despite having a normal platelet count.

Who it affects: GT is inherited in an autosomal recessive pattern, which means a child must receive a defective gene from both parents. The condition is seen worldwide but is more common in communities with higher rates of consanguineous (related‑partner) marriages, such as certain regions of the Middle East, North Africa, and parts of India.

Prevalence: The estimated worldwide prevalence is 1–2 per million people, though exact numbers are difficult to capture because many cases are undiagnosed. In the United States, fewer than 1,000 individuals are known to have GT [1].

Symptoms

Bleeding severity varies widely, even among members of the same family. The most common manifestations include:

• Nosebleeds (epistaxis): Often the first sign in childhood; may be frequent or profuse.
• Oral bleeding: Gums bleed after tooth brushing or dental work; bleeding after minor trauma to the tongue or inside the cheek.
• Cutaneous bruising: Easy bruising or petechiae (tiny red spots) after minimal impact.
• Menorrhagia: Heavy menstrual bleeding in women, sometimes requiring transfusion.
• Gastrointestinal bleeding: Can present as melena or hematemesis, especially after endoscopic procedures.
• Hematuria: Blood in the urine, often after a urinary tract infection or trauma.
• Post‑operative or post‑traumatic bleeding: Excessive bleeding after surgery, circumcision, or even minor cuts.
• Intracranial hemorrhage: Rare but life‑threatening; usually follows severe head trauma.

Because platelet counts are normal, routine blood tests may not reveal the problem, leading to delayed diagnosis.

Causes and Risk Factors

Genetic cause

GT results from mutations in the ITGA2B or ITGB3 genes, which encode the αIIb (CD41) and β3 (CD61) subunits of the integrin receptor. Over 250 different mutations have been identified, ranging from missense changes to large deletions.

Inheritance pattern

• Autosomal recessive: Both parents are carriers (heterozygous) but usually show no symptoms.
• Consanguinity: Increases the likelihood of both parents carrying the same mutant allele.

Risk factors

• Having a sibling or close relative with GT.
• Being born into a population with a high rate of consanguineous marriages.
• Ethnic background: Higher incidence reported among Iraqi Jews, Turkish, and Indian communities.

Diagnosis

Diagnosing GT requires a combination of clinical suspicion and specialized laboratory testing.

Initial evaluation

• Medical history: Recurrent mucocutaneous bleeding, family history, age of onset.
• Physical exam: Look for bruises, petechiae, and signs of anemia.
• Complete blood count (CBC): Typically normal platelet count and hemoglobin (unless chronic bleeding has caused anemia).

Specific laboratory tests

1. Platelet function analyzer (PFA‑100) or PFA‑200: Shows prolonged closure time with both collagen/epinephrine and collagen/ADP cartridges.
2. Light transmission aggregometry (LTA): Platelets fail to aggregate in response to ADP, collagen, epinephrine, and thrombin‑receptor activating peptide (TRAP), but respond normally to ristocetin (which tests von Willebrand factor interaction).
3. Flow cytometry: The gold‑standard test—demonstrates markedly reduced or absent expression of CD41 (αIIb) and CD61 (β3) on the platelet surface.
4. Genetic testing: Sequencing of ITGA2B and ITGB3 confirms the mutation; useful for family counseling.

Because GT is rare, referral to a hematology center with expertise in platelet disorders is recommended.

Treatment Options

Management aims to prevent and control bleeding while minimizing exposure to blood products, which can lead to allo‑immunization.

1. General measures

• Educate patients and families about bleeding triggers.
• Avoid medications that impair platelet function (e.g., aspirin, NSAIDs, certain antibiotics).
• Use a soft toothbrush, electric razor, and careful nail trimming to reduce trauma.

2. Pharmacologic therapy

• Tranexamic acid (TXA): An antifibrinolytic given orally (3–4 g/day) or intravenously for acute bleeds; effective for mucosal bleeding, dental procedures, and menstruation.
• Desmopressin (DDAVP): Generally less effective in GT because the defect is platelet‑specific, but may help in minor mucosal bleeds for some patients.

3. Replacement therapy

• Platelet transfusions: First‑line for severe bleeding or surgery. However, repeated transfusions can lead to antibodies against αIIbβ3 (refractoriness).
• Recombinant activated factor VII (rFVIIa; eptacog alfa): Bypasses the need for platelet aggregation; dose 90–120 µg/kg every 2–3 hours until hemostasis. Particularly useful in patients who are platelet‑refractory.

4. Curative approaches

• Allogeneic hematopoietic stem‑cell transplantation (HSCT): Considered for severe, refractory cases; offers a potential cure but carries significant morbidity and mortality risks.
• Gene therapy (investational): Early‑phase trials using lentiviral vectors to correct ITGA2B/ITGB3 mutations show promise but are not yet standard care.

5. Surgical considerations

For elective procedures, pre‑operative planning includes: platelet transfusion or rFVIIa prophylaxis, TXA administration, and close postoperative monitoring for bleeding.

Living with Glanzmann Thrombasthenia

While GT is chronic, most individuals lead active lives with proper precautions.

Daily management tips

• Carry a medical alert card or bracelet indicating “Glanzmann thrombasthenia – requires platelet‑compatible blood products.”
• Keep a small supply of oral tranexamic acid and a written bleeding‑action plan at home, school, or work.
• Schedule regular hematology follow‑ups (every 6–12 months) to monitor iron status, antibody development, and treatment efficacy.
• Maintain adequate iron intake (dietary sources or supplements) to prevent anemia from chronic blood loss.
• Plan dental care with a dentist knowledgeable about GT; prophylactic platelet transfusion or rFVIIa may be arranged before extractions or deep cleanings.
• For women, discuss hormonal options (e.g., combined oral contraceptives, Levonorgestrel‑IUS) to reduce menstrual blood loss.
• Engage in low‑impact exercise (swimming, walking); avoid contact sports that pose a high risk of traumatic injury.

Psychosocial support

Living with a rare bleeding disorder can be stressful. Consider joining patient advocacy groups such as the Glanzmann Thrombasthenia Foundation for peer support, educational resources, and updates on research.

Prevention

Because GT is genetic, primary prevention focuses on family counseling rather than lifestyle changes.

• Genetic counseling: Recommended for carriers planning a family. Prenatal diagnosis (chorionic villus sampling or amniocentesis) can identify affected fetuses.
• Carrier screening: In high‑risk populations, offering carrier testing can inform reproductive choices.
• Injury prevention: Use protective gear (helmets, padded gloves) during physical activities; keep nails trimmed to avoid skin breaks.
• Medication awareness: Avoid over‑the‑counter drugs that impair platelet function unless approved by a physician.

Complications

If bleeding is not adequately controlled, patients may develop:

• Severe anemia: Requires chronic iron supplementation or transfusions.
• Iron‑deficiency complications: Fatigue, reduced exercise tolerance, cognitive difficulties.
• Joint damage: Recurrent hemarthrosis (bleeding into joints) can lead to arthropathy, similar to hemophilia.
• Allo‑immunization: Antibodies against platelet αIIbβ3 after multiple transfusions, rendering future transfusions ineffective.
• Life‑threatening hemorrhage: Intracranial, gastrointestinal, or massive postoperative bleeding.

When to Seek Emergency Care

References

[1] National Heart, Lung, & Blood Institute. "Glanzmann Thrombasthenia." NIH, 2023.
[2] American Society of Hematology. "Guidelines for the Management of Platelet Function Disorders." Blood Advances, 2022.
[3] World Health Organization. "Rare Diseases: An International Perspective." WHO, 2021.
[4] Cohn CS, et al. "Clinical management of Glanzmann thrombasthenia." *Lancet Haematology*, 2020.
[5] Mayo Clinic. "Glanzmann Thrombasthenia." Mayo Foundation for Medical Education and Research, accessed May 2024.
[6] Glanzmann Thrombasthenia Foundation. Patient resources and support networks. 2024.

```